Paul E. Greenberg

Managing Principal and Director, Health Economics


Paul E. Greenberg



M.S., applied microeconomics and finance, MIT Sloan School of Management; M.A., economics, University of Western Ontario; A.B., economics, Vassar College

Summary of Experience

Mr. Greenberg, director of Analysis Group's Health Care practice, specializes in health economics, both in health outcomes research and in complex business litigation. He consults to pharmaceutical, biotechnology, and medical device companies concerning the health economics profiles of specific diseases and medical products. He has overseen cost-of-illness research relating to numerous physical and psychiatric disorders, as well as pharmacoeconomic assessments of the cost-effectiveness of drugs based on data gathered in clinical trials and administrative claims files. Mr. Greenberg's health outcomes research has been published in leading medical, health economics, and managed care journals.

Mr. Greenberg draws upon the methodological tools and data sources commonly used in an outcomes research context to analyze problems that emerge in litigation involving health care products (e.g., pharmaceuticals, biotechnology, and medical devices). More specifically, Mr. Greenberg's experience includes performing economic analyses and presenting findings to U.S. Attorney's Office investigators in numerous cases with allegations of off-label promotion, kickback, and/or pricing issues, in which Food, Drug and Cosmetic Act, False Claims Act, and/or Anti-Kickback Statute violations have been alleged. He has provided economic consulting support in connection with class certification, liability, and damages in cases involving allegations of antitrust, product failure, product fraud, and/or patent infringement. Mr. Greenberg has also provided strategic assistance to counsel at various key points in litigation, including pretrial discovery, settlement negotiations, and trial preparation.

Mr. Greenberg currently serves on the editorial boards of PharmacoEconomics, Journal of Medical Economics, and Expert Opinion on Pharmacotherapy. In addition, he has served on the editorial boards of Law360's Life Sciences and Health Care electronic newsletters as well as Expert Review of Pharmacoeconomics & Outcomes Research. He is a recipient of the Social Sciences and Humanities Research Council of Canada award for graduate study in Canada, as well as The Wall Street Journal Award for economics. Mr. Greenberg is a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the International Health Economics Association (iHEA).

En Français

Selected Publishing